DE2541429A1 - Orotsaeurederivat und dieses enthaltende arzneimittel - Google Patents
Orotsaeurederivat und dieses enthaltende arzneimittelInfo
- Publication number
- DE2541429A1 DE2541429A1 DE19752541429 DE2541429A DE2541429A1 DE 2541429 A1 DE2541429 A1 DE 2541429A1 DE 19752541429 DE19752541429 DE 19752541429 DE 2541429 A DE2541429 A DE 2541429A DE 2541429 A1 DE2541429 A1 DE 2541429A1
- Authority
- DE
- Germany
- Prior art keywords
- orotic acid
- acid derivative
- diethylamino
- products containing
- medicinal products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical class OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 title claims description 11
- 229940126601 medicinal product Drugs 0.000 title description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000002830 appetite depressant Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229960005010 orotic acid Drugs 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7431553A FR2285120A1 (fr) | 1974-09-18 | 1974-09-18 | Orotate de 2-(diethylamino)-1-phenyl-propanone et son procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2541429A1 true DE2541429A1 (de) | 1976-04-01 |
Family
ID=9143207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752541429 Withdrawn DE2541429A1 (de) | 1974-09-18 | 1975-09-17 | Orotsaeurederivat und dieses enthaltende arzneimittel |
Country Status (8)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2141322C1 (ru) * | 1997-08-12 | 1999-11-20 | Голощапов Николай Михайлович | Иммуномодулятор с антимикобактериальной активностью "изофон", способ его получения и применения |
| RU2136668C1 (ru) * | 1997-10-07 | 1999-09-10 | Голощапов Николай Михайлович | N,n'-(сульфонилди-1,4-фенилен)бис(n'',n''- диметилформамидин)1,2,3,4-тетрагидро-6-метил-2,4- диоксо-5-пиримидинсульфонат, стимулирующий клеточный метаболизм и обладающий иммунотропной и антимикобактериальной активностью |
-
1974
- 1974-09-18 FR FR7431553A patent/FR2285120A1/fr active Granted
-
1975
- 1975-09-02 CH CH1135475A patent/CH572912A5/xx not_active IP Right Cessation
- 1975-09-15 GB GB3774275A patent/GB1511517A/en not_active Expired
- 1975-09-16 JP JP11202575A patent/JPS5161616A/ja active Pending
- 1975-09-16 NL NL7510895A patent/NL7510895A/xx not_active Application Discontinuation
- 1975-09-16 LU LU73413A patent/LU73413A1/xx unknown
- 1975-09-17 DE DE19752541429 patent/DE2541429A1/de not_active Withdrawn
- 1975-09-17 BE BE160133A patent/BE833524A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NL7510895A (nl) | 1976-03-22 |
| LU73413A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-04-13 |
| FR2285120A1 (fr) | 1976-04-16 |
| BE833524A (fr) | 1976-01-16 |
| JPS5161616A (en) | 1976-05-28 |
| GB1511517A (en) | 1978-05-17 |
| FR2285120B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-07-21 |
| CH572912A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0240829B1 (de) | Cancerostatisches Mittel | |
| DE2921072A1 (de) | Phenoxyalkylcarbonsaeure-derivate und diese verbindungen enthaltende arzneimittel | |
| AT389871B (de) | Verfahren zur herstellung von beta, gamma -dihydropolyprenylalkoholderivaten | |
| DE3424781C2 (de) | Verwendung von L-Carnosin zur Tumorbehandlung | |
| DE2552869C2 (de) | Pharmazeutische Zusammensetzungen mit Piperidylindol-Derivaten | |
| DE1949813C3 (de) | 3-<4-Pvridyl)-4-(2-hydroxvphenyl)-5-alkyl-pyrazole | |
| DE69313640T2 (de) | Zink-tranexamat derivat | |
| DE3888541T2 (de) | Verbesserung der toxizitätskurven in der chemotherapie. | |
| DE2434929C2 (de) | p-Acetylaminophenolester von Phenylsalicylsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE69125204T2 (de) | Therapeutische Anwendung von Histamin-H3-Agonisten, neue Wirkstoffe und Verwendung zur Herstellung von Arzneimitteln | |
| DE2541429A1 (de) | Orotsaeurederivat und dieses enthaltende arzneimittel | |
| DE2238280A1 (de) | Furanderivate enthaltende arzneimittel und neue n-furoylmorpholinverbindungen | |
| DE2411823A1 (de) | Verwendung von 1,2,4-triazol-3-carboxamiden und -thiocarboxamiden als antivirenmittel | |
| CH657127A5 (de) | Antivirales mittel. | |
| DE1911467A1 (de) | Mittel zum Senken des Cholesterinspiegels | |
| DE2605243A1 (de) | Pyrazolessigsaeurehaltiges arzneimittel | |
| EP0001061B1 (de) | Neue Polypeptide, ihre Herstellung und Heilmittel, die diese Polypeptide enthalten | |
| DE1964504B2 (de) | Arzneimittel zur behandlung oedematoeser zustaende und hypertensionen | |
| DE2625053B2 (de) | Arzneimittel zur Kontrolle von Leberkrankheiten | |
| DE3781339T2 (de) | Therapeutisches mittel fuer gastritis. | |
| DE3523263A1 (de) | Arzneimittel | |
| DE2615129B2 (de) | Tripeptide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
| DE3706431C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2362813C3 (de) | Sbeta-Cycloalkyloxy-iealpha-cyan-pregn-Sen-20-one, Verfahren zu deren Herstellung sowie diese enthaltende Mittel Syntex (U.S.A.) Inc., Palo Alto, Calif. (V.St.A.) | |
| DE2221281B2 (de) | Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8139 | Disposal/non-payment of the annual fee |